RESEARCH ARTICLE


Safety of Intra-Articular Use of Atelocollagen for Enhanced Tissue Repair



Elise M Magarian 1, Patrick Vavken 1, Susan A Connolly 2, Ashley N Mastrangelo 1, Martha M Murray*, 1
1 Department of Orthopaedic Surgery, Children’s Hospital Boston, 300 Longwood Ave, Boston, MA 02115, USA
2 Department of Radiology, Children’s Hospital Boston, 300 Longwood Ave, Boston, MA 02115, USA


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 1735
Abstract HTML Views: 968
PDF Downloads: 254
Total Views/Downloads: 2957
Unique Statistics:

Full-Text HTML Views: 756
Abstract HTML Views: 565
PDF Downloads: 172
Total Views/Downloads: 1493



© Magarian et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Department of Orthopaedic Surgery, Children’s Hospital of Boston, 300 Longwood Ave, Boston, MA 02115, USA; Tel: 617 355 7497; Fax: 617 730 0459; E-mail: Martha.murray@childrens.harvard.edu


Abstract

Collagen is an important biomaterial in intra-articular tissue engineering, but there are unanswered questions about its safety. We hypothesize that the addition of type-I-collagen for primary repair of the Anterior Cruciate Ligament (ACL) might result in a local and systemic reaction in a porcine model after 15 weeks as demonstrated by joint effusion, synovial thickening, elevated intraarticular and systemic leukocyte counts. Further, this reaction might be aggravated by the addition of a platelet concentrate. Eighteen porcine ACLs were transected and repaired with either sutures (n=6), a collagen sponge (n=6), or a collagen-platelet-composite (CPC; n=6). Twelve intact contralateral knees served as controls (n=12). No significant synovial thickening or joint effusion was seen in the collagen-treated knees. Synovial fluid leukocyte counts showed no significant differences between surgically treated and intact knees, and no differences were seen in leukocyte counts of the peripheral blood. The addition of a platelet concentrate to the knee joint resulted in lower serum levels of IL-1β, but serum levels of TNF-α were not significantly different between groups. In conclusion, the presence of collagen, with or without added platelets, did not increase the local or systemic inflammatory reactions following surgery, suggesting that Type I collagen is safe to use in the knee joint.

Keywords: ACL, biomaterials, collagen, safety, tissue engineering.